Bone Biologics Corp.
13F holders, Q4 2024 (December 31)7holders
2new positions
3sold out
$0.93avg. 13F price*
At the end of Q4 2024, 7 institutions reported holding Bone Biologics Corp. in their 13F filings, unchanged from Q3 2024. 2 opened new positions and 3 sold out. The largest holders were UBS Group AG ($21K), Geode Capital Management, LLC ($14K) and HRT Financial LP ($13K).
- Company
- Bone Biologics Corp.
- CUSIP
- 098070501
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $19K |
| Exits | 3 | $63K |
All 13F filers, Q3 2024 → Q4 2024: 21,910 shares bought and 47,977 shares sold, net −26,067 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| UBS Group AG | 0.00% | Reduce -33.4% | 21,866 | $21K |
| Geode Capital Management, LLC | 0.00% | New | 15,355 | $14K |
| HRT Financial LP | 0.00% | Reduce -34.2% | 14,658 | $13K |
| Citigroup Inc. | 0.00% | New | 4,948 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +89.6% | 3,387 | $3K |
| Bank of America Corp. | 0.00% | Add +42.9% | 20 | $19 |
| SBI Securities Co., Ltd. | 0.00% | — | 1 | $1 |
"% of holder's portfolio" is BONE BIOLOGICS CORP's weight in each manager's 13F, not the share of Bone Biologics Corp. the manager owns.